Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014144
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company which discovers and develops therapeutics for the treatment of solid tumors and blood cancers. Its lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogenes or signaling pathways that drive cancer growth. The company’s pipeline product portfolio includes Tipifarnib – HRAS, Tipifarnib – PTCL, Tipifarnib – MDS, Tipifarnib- CMML and others. Kura Oncology’s phase I and pre-clinical stage products are KO-947, a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) and KO-539 inhibitor program inhibits the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias. It targets therapeutic areas which include T-cell lymphoma, melanoma, lung and pancreatic cancers, mixed lineage leukemia and other cancers. Kura Oncology is headquartered in La Jolla, California, the US.

Kura Oncology Inc (KURA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Venture Financing 12
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Merger 13
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Licensing Agreements 14
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Equity Offering 17
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc – Key Competitors 23
Kura Oncology Inc – Key Employees 24
Kura Oncology Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 26
May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 27
Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 29
Nov 07, 2016: Kura Oncology Reports Third Quarter 2016 Financial Results 30
Aug 10, 2016: Kura Oncology Reports Second Quarter 2016 Financial Results 31
May 11, 2016: Kura Oncology Reports First Quarter 2016 Financial Results 32
Mar 17, 2016: Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results 33
Corporate Communications 35
Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 35
Product News 36
01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 36
Clinical Trials 37
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 37
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 38
Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 39
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 40
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 41
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 42
Dec 01, 2016: Kura Oncology Presents Data on Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 43
Dec 01, 2016: Kura Oncology Presents Preclinical Data on KO-947 the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 44
Nov 15, 2016: Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc, Key Competitors 23
Kura Oncology Inc, Key Employees 24
Kura Oncology Inc, Other Locations 25

★海外企業調査レポート[Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Delaware Municipal Electric Corporation, Inc.:企業の戦略的SWOT分析
    Delaware Municipal Electric Corporation, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Owlstone Medical Ltd:企業の製品パイプライン分析2018
    Summary Owlstone Medical Ltd (Owlstone Medical), formerly Tiger Dawn Ltd, is a diagnostic company. The company develops and commercializes breathalyzers for use in clinical diagnostics and precision medicines. It offers FAIMS Technology for medical applications; Lonestar for disease biomarker detect …
  • Broadspectrum (Australia) Pty Ltd:企業の戦略的SWOT分析
    Broadspectrum (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Magellan Midstream Partners, L.P.:企業の戦略・SWOT・財務情報
    Magellan Midstream Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Magellan Midstream Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cox & Kings Limited:企業の戦略・SWOT・財務分析
    Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report Summary Cox & Kings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Jardine Lloyd Thompson Group plc:企業のM&A・事業提携・投資動向
    Jardine Lloyd Thompson Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jardine Lloyd Thompson Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • BrightSpring Health Services:企業の戦略・SWOT・財務分析
    BrightSpring Health Services - Strategy, SWOT and Corporate Finance Report Summary BrightSpring Health Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • F5 Networks, Inc.:企業の戦略・SWOT・財務情報
    F5 Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary F5 Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • The Pack Corporation:企業の戦略・SWOT・財務分析
    The Pack Corporation - Strategy, SWOT and Corporate Finance Report Summary The Pack Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bachem Holding AG (BANB):製薬・医療:M&Aディール及び事業提携情報
    Summary Bachem Holding AG (Bachem) is a technology-based biochemical company which develops and manufactures peptides and complex organic molecules including active pharmaceutical ingredients and biochemicals for research purposes. Bachem offers its products and services to the pharmaceutical and bi …
  • Shangri-La Hotels (Malaysia) Berhad:戦略・SWOT・企業財務分析
    Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Centogene AG:医療機器:M&Aディール及び事業提携情報
    Summary Centogene AG (Centogene) is a biotechnology and genetic diagnostic company which offers genetic testing for rare hereditary disorders. The company provides diagnostic services including whole genome sequencing, whole exome sequencing, clinical exome sequencing, NGS panel genomic, carrier scr …
  • Constant Contact, Inc.:企業の戦略・SWOT・財務分析
    Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report Summary Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Grant Thornton International Ltd.:戦略・SWOT・企業財務分析
    Grant Thornton International Ltd. - Strategy, SWOT and Corporate Finance Report Summary Grant Thornton International Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Institut Gustave Roussy-製薬・医療分野:企業M&A・提携分析
    Summary Institut Gustave Roussy (IGR) is a cancer research institute that offers healthcare services to patients suffering from cancer and conducts research to identify new therapies. The institute provides treatment for the diseases that include endocrine tumours, childhood cancer, gynecological ca …
  • Tulane University:製薬・医療:M&Aディール及び事業提携情報
    Summary Tulane University (Tulane) is an educational service provider that provides biomedical courses and research programs. The university provides educational courses in the fields of architecture, business, law, liberal arts, medicine, public health and tropical medicine, science, engineering, a …
  • KeyCorp (KEY):企業の財務・戦略的SWOT分析
    KeyCorp (KEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Fomento de Construcciones y Contratas S.A.:企業の戦略・SWOT・財務分析
    Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report Summary Fomento de Construcciones y Contratas S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company which discovers and develops therapeutics for the treatment of solid tumors and blood cancers. Its lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogene …
  • Northern Minerals Ltd (GPP):企業の財務・戦略的SWOT分析
    Summary Northern Minerals Ltd (Northern Minerals) formerly known as Greenpower Energy Limited, is a mining, exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆